11/6/2026

speaker
Conference Operator
Operator

Good day and welcome to Cresco Labs' third quarter 2026 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press the star key, then one on your touchtone phone. To withdraw your question, please press the star key, then 1 again. Please note this event is being recorded. I would now like to turn the call over to TJ Cole, Senior Vice President, Corporate Development and Investor Relations for Cresco Labs. Please go ahead.

speaker
TJ Cole
Senior Vice President, Corporate Development and Investor Relations, Cresco Labs

Thank you. Good morning. Welcome to Cresco Labs' third quarter 2026 earnings conference call. On the call today, we have Chief Executive Officer and Co-Founder Charles Bachtell, Interim Chief Financial Officer Mark Stortz, and President Greg Butler will be available for the Q&A. Prior to this call, we issued our third quarter earnings press release, which has been filed on CDAR and is available on our investor relations website. These preliminary results for the third quarter are provided prior to completion of all internal and external reviews and therefore are subject to adjustment until the filing of the company's quarterly financial statements. We filed our corresponding financial statements and MD&A for the quarter ended September 30th, 2026 on CDAR and EDGAR earlier this morning. Before we begin, I want to remind you that statements made on today's call may contain forward looking information. Actual results may differ materially. The risks, uncertainties, and other factors that could influence actual results are described in our earnings press release and in the most recent annual information form and MD&A filed with the securities regulators. This call also contains non-GAAP measures also outlined in our earnings press release and in the MD&A filed with the securities regulators. Please also note that all financial information on today's call is presented in U.S. dollars and all interim financial information is unaudited. With that, I'll turn the call over to Charlie.

speaker
Charles Bachtell
Chief Executive Officer and Co-Founder, Cresco Labs

Good morning, everyone, and thank you for joining Cresco Labs' third quarter 2026 earnings call. The quarter delivered is planned. We expected Q3 to look a lot like Q2 on revenue, while we worked through higher cost inventory, integrated new stores, and brought Kentucky online. We generated $173 million in revenue, up 5% year over year. We produced $81 million in adjusted gross profit. We produced $35 million in adjusted EBITDA, resulting in a 20% margin. And we generated $26 million in operating cash flow, up from $15 million in Q2, and $21 million in free cash flow. Cash is our North Star. In this quarter, the business converted over 60% of adjusted EBITDA into free cash flow. The Cresco team executed this quarter as we closed on an acquisition, improved cultivation, and ramped up a new state, all while keeping the base business running at a high level. I'll now walk you through the quarter by touching on three themes. First, executing on our growth plan. Second, winning where we operate. And third, building the company for its next chapter. First, our growth plan. Remain disciplined and consistent in our growth strategy. Where we lead, we go deeper. Where we see structural advantages, we find compelling inroads. And every opportunity is evaluated on the same thresholds. It must have a creative economics and be in a market with a durable structure. On September 2nd, we closed the acquisition of the nine Pennsylvania dispensaries, a state where our scaled position gives us operating leverage. While the state approval process took longer than anticipated, We can now fully implement our operating model from top to bottom. In Q4, we're putting the playbook into effect and working toward moving the stores under the Sunnyside banner. With 27 locations alongside the number one branded share, we operate the largest retail network in Pennsylvania, the second largest medical market in the country. In Ohio, we captured a full quarter of contribution from our completed eight store retail network, and we've also done important work to upgrade our cultivation. In the first half of the year, we transitioned our greenhouses to allow full environmental control and under canopy lighting and we made similar improvements in Massachusetts. These are great examples of how we invest targeted capital light and a high level of execution certainty. While this construction had an impact on cultivation in the first half of the year, resulting in less sellable material and higher cost products that we're selling through in the second half of 2026, The harvests coming out of Ohio and Massachusetts today have materially higher yields, and that additional supply will let us expand product sizes and categories in 2027. We're also encouraged by Ohio's enforcement of intoxicating hemp rules, which can serve as a successful case study for other states. The entire market is up over 30% year over year, and consumers are embracing safer products that are lab tested, accurately labeled, and sold through the regulated retail channel. In Kentucky, we completed our first full quarter of commercial SIVs. The market is developing broadly in line with the ramp up we expected, and subsequent to quarter end, we opened our first Sunnyside dispensary in the state on October 23rd. New medical programs take time to build, and Kentucky's contribution in the near term will be modest. This is a multi-year opportunity, and we're pacing our investment to market growth. Second, we win where we operate. Procresco winning means managing competitive and pricing pressure while running the most productive retail in our markets, getting more out of every square foot of cultivation, and building brands that consumers revisit again and again. Looking at retail productivity, Sunnyside dispensaries generate nearly 30% more revenue per store than state averages. In Illinois, Ohio, and Pennsylvania, that productivity translates into a top two retail share position in each of these core states. Our House of Brands products achieve in wholesale what Sunnyside does in retail. They bring repeat consumers back. In Pennsylvania, we expanded our number one branded product market share lead. In Illinois, we lead the state in flour, edibles, and concentrates market share. While we've lost share in vape, this is by design. The category's growth is driven by larger formats sold at the same price, pushing price per gram down by more than a third in two years. We're not chasing that trend. Our vape portfolio commands the highest price per gram of any major producer in the state. In Massachusetts, we lead in market share led by our branded flower share. Winning where we operate also means innovating where we operate. We're thrilled to be introducing two exciting innovations that give consumers an approachable way to choose cannabis for more occasions. Last month, we launched Slips, an oral pouch under the high supply brand that landed on Sunnyside shelves in Illinois in four and 10 milligram formats. Consumers are already enthusiastic about the unique, convenient format that allows for discreet, fast-acting consumption. This week, our wonder brand introduced 5 mg single-serving beverage mixes, designed for occasions like exercising, sleeping, or socializing. Learning from the hemp beverage boom and leaning into the wellness beverage trend, each mix also includes ingredients such as creatine and caffeine for the exercise formulation, and chamomile and melatonin for the sleep formulation. Both products align with a broader shift in consumer behavior towards products that are portable, low profile and easy to incorporate into everyday routines. We're initially launching in our own Illinois stores because our retail and loyalty data lets us measure repeat purchases precisely. It's a test and learn approach and we'll scale using that data. Cannabis is still poised to be one of the largest consumer goods categories in the country. which is why Cresco continues applying our CPG playbook to understand unmet consumer needs and occasions, develop products that meet those needs, and build trusted brands that provide meaningful choices. I couldn't be prouder of this team as they continued expanding traditional cannabis forms to reach new consumers and wellness categories. And third, we're building the company for its next chapter. Last quarter, we said that we were executing on everything within our control so that when federal regulations allow, we'll be ready to capitalize on the next phase of regulated cannabis. Last week at our annual general and special meeting, shareholders approved three special resolutions, each with over 94% of votes cast in favor. Each of the resolutions are structural steps that together do three things. They simplify our corporate structure. They align the company with the U.S. investor base that will increasingly own this industry as it normalizes. and they put the pieces in place to prepare for uplisting on a senior U.S. exchange. This means we are ready for CRESCO's next phase as we watch federal reform continue to unfold. The federal backdrop continues to move in our direction. Earlier this week, our medical operations began receiving DEA registrations under Schedule 3. The administrative process and broader rescheduling continues to progress. And in December, federal restrictions on intoxicating hemp are set to take effect, which, as we've seen in Ohio, supports the health of both consumers and this industry. That said, we don't build our plan around federal reform timelines. As always, we plan for the business we have today so that we're well positioned, regardless of future reform outcomes. Before I hand it over, I want to welcome Mark Stortz, who is serving as our interim chief financial officer. With that, I'll let Mark walk you through our Q3 financial performance in more detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation